Primmune Therapeutics

Developer of immunotherapies for treating cancer

placeSan Diego, California, United States calendar_todayFounded 2017 groups9 employees language primmunerx.com

Innovation

3 patent families (2 granted) — focus: Chemistry & metallurgy; filing pace slowing. Cited 302 times.

YearFilings
20191
20201
20212
20223
20233
20242
20252
20261

Investor mix

10 investors on record; lead investors include CAM Capital, BioBrit, BioRock Ventures, Bioqube Ventures.

Investor typeCountShare
Venture capital440%
Private equity220%
Accelerator & incubator110%
Other / undisclosed330%
Coming soon